220 related articles for article (PubMed ID: 22012607)
21. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
[TBL] [Abstract][Full Text] [Related]
22. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
23. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
[TBL] [Abstract][Full Text] [Related]
25. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.
Kobe C; Dietlein M; Kriz J; Furth C; Fuchs M; Borchmann P; Engert A; Eich HT
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1419-28. PubMed ID: 20836677
[TBL] [Abstract][Full Text] [Related]
26. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
[TBL] [Abstract][Full Text] [Related]
27. PET imaging in pediatric Hodgkin's lymphoma.
Hudson MM; Krasin MJ; Kaste SC
Pediatr Radiol; 2004 Mar; 34(3):190-8. PubMed ID: 14745528
[TBL] [Abstract][Full Text] [Related]
28. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
[TBL] [Abstract][Full Text] [Related]
29. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
30. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
31. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
Pommier P; Dussart S; Girinsky T; Chabaud S; Lagrange JL; Nguyen TD; Beckendorff V; D'Hombres A; Artignan X; Bondiau PY; Carrie C; Giammarile F
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):823-8. PubMed ID: 20452732
[TBL] [Abstract][Full Text] [Related]
32. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
Adams HJA; Kwee TC
Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
[TBL] [Abstract][Full Text] [Related]
33. [Therapy of Hodgkin lymphoma: chances of remission are good, treatment tolerance needs improvement].
Bischoff M
MMW Fortschr Med; 2011 Oct; 153(41):17. PubMed ID: 22046834
[No Abstract] [Full Text] [Related]
34. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
35. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma.
Robertson VL; Anderson CS; Keller FG; Halkar R; Goodman M; Marcus RB; Esiashvili N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):324-32. PubMed ID: 20646867
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary lesions in early response assessment in pediatric Hodgkin lymphoma: prevalence and possible implications for initial staging.
Stoevesandt D; Ludwig C; Mauz-Körholz C; Körholz D; Hasenclever D; McCarten K; Flerlage JE; Kurch L; Wohlgemuth WA; Landman-Parker J; Wallace WH; Fosså A; Vordermark D; Karlén J; Cepelová M; Klekawka T; Attarbaschi A; Hraskova A; Uyttebroeck A; Beishuizen A; Dieckmann K; Leblanc T; Daw S; Steglich J
Pediatr Radiol; 2024 May; 54(5):725-736. PubMed ID: 38296856
[TBL] [Abstract][Full Text] [Related]
37. Overview of early response assessment in lymphoma with FDG-PET.
MacManus MP; Seymour JF; Hicks RJ
Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
[TBL] [Abstract][Full Text] [Related]
38. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
Araf S; Montoto S
Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
[TBL] [Abstract][Full Text] [Related]
39. Current Role of FDG-PET in Pediatric Hodgkin's Lymphoma.
Kluge R; Kurch L; Georgi T; Metzger M
Semin Nucl Med; 2017 May; 47(3):242-257. PubMed ID: 28417854
[TBL] [Abstract][Full Text] [Related]
40. Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy?
Yeoh KW; Mikhaeel NG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):14-20. PubMed ID: 22578540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
